Sublingual and oral immunotherapy - 24/08/11
Doi : 10.1016/j.iac.2004.07.001
Giorgio Walter Canonica, MD ⁎ 
, Enrico Compalati, MD, Federica Fumagalli, MD, Giovanni Passalacqua, MD
, Enrico Compalati, MD, Federica Fumagalli, MD, Giovanni Passalacqua, MD Allergy and Respiratory Diseases, Department of Internal Medicine, University of Genoa, Padiglione Maragliano, L.go R. Benzi 10, Genoa 16132, Italy
*Corresponding author
Résumé |
Sublingual immunotherapy (SLIT) is a viable alternative to the subcutaneous route for the treatment of respiratory allergy, whereas the pure oral route has been abandoned because of its lack of efficacy. The main distinctive feature of SLIT is its optimal safety profile, which has been demonstrated in adults and children. The indications for SLIT are similar to those for the subcutaneous route. A long-lasting effect has been demonstrated for the sublingual route, but data are needed to determine the optimal dose and the preventive effect in asthma.
Le texte complet de cet article est disponible en PDF.Plan
| This article was supported partially by Associazione Ricerca Malattie Immunologiche e Allergiche (ARMIA). |
© 2004
Elsevier Inc. Tous droits réservés.
Vol 24 - N° 4
P. 685-704 - novembre 2004 Retour au numéro
Article précédent
- Chemokine receptors: understanding their role in asthmatic disease
- Allison L. Miller, Nicholas W. Lukacs
- Food allergy therapy
- Anna Nowak-Wegrzyn, Hugh A. Sampson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?